Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of 5-Aminolevulinic Acid (5-ALA) Based Novel Tranbroncheal Photodynamic Ablation for Peripheral Lung Malignant Tumors

NCT06679712 is registered in ClinicalTrials.gov with Taoyuan General Hospital as lead sponsor.

NCT NCT06679712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06679712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of 5-Aminolevulinic Acid (5-ALA) Based Novel Tranbroncheal Photodynamic Ablation for Peripheral Lung Malignant Tumors
Lead sponsor
Taoyuan General Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 1, 2024
Completion date
December 31, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer - non small cell, lung metastases from any primary